The present invention relates to the genetic engineering field of angiogenesis-targeted therapy. Particularly, a recombinant human endostatin adenovirus injection is used along with certain antitumor agents for treating specific tumors. The methods of the invention offer significant improvement of effective response rate, disease control rate, survival and quality of life. The injection and treatment has no significant adverse reactions and side effects.
